Join ASNC

Masterclass in Cardiac Amyloidosis

AGENDA | FACULTY

Masterclass in Cardiac Amyloidosis:
Disease Spectrum, Diagnosis and Management
March 8-10, 2024

Registration is complimentary!
 

Join us March 8-10, 2024 for the virtual Masterclass in Cardiac Amyloidosis: Disease Spectrum, Diagnosis and Management. This program is offered free of charge.

Led by Program Chair, Saurabh Malhotra, MD, MPH, FASNC, Masterclass features multidisciplinary content that today's practitioners need to keep current in the rapidly advancing field of cardiac amyloidosis.


 

Masterclass will cover:

  • the pathogenesis of cardiac amyloidosis;
  • diagnostic techniques and pitfalls;
  • management strategies;
  • mechanisms to facilitate early diagnosis; and
  • treatment and management.


The program will feature in-depth sessions led by expert cardiologists, multimodality imagers, hematologists, and neurologists to discuss the disease spectrum, diagnosis, and management of cardiac amyloidosis.

New This Year!
A two-hour session for technologists, "Amyloidosis for Technologists: Tips and Tricks from Experts" on Saturday, March 9 from 1-3pm ET.

This session is essential for technologists who are or will be performing radionuclide imaging for cardiac amyloidosis. Leading experts will guide you through an overview of the disease, image acquisition and processing and recommendations to avoid potential pitfalls.

Credits

Earn up to 11* CME/MOC credits.
2* CE credits for the technologist session, Amyloidosis for Technologists: Tips and Tricks from Experts.

Faculty


Learning Objectives

By the end of the program, you should be able to:

  • Describe amyloidosis, including specific types, cardiac features, and disease burden.
  • Identify barriers to identification and diagnosis of patients suspected of ATTR.
  • Summarize the diagnostic evaluation for cardiac amyloidosis including multimodality imaging and laboratory testing and identify prognostic markers.
  • Recognize patients at risk for hereditary ATTR (hATTR) and wild-type ATTR (wtATTR).
  • Explain the importance of genetic testing in hATTR.
  • Discuss the therapeutic landscape and impact on disease burden.
  • Define appropriate treatment and management strategies for patients with heart failure.
  • Formulate strategies for development of a multidisciplinary care team.
  • Evaluate potential community outreach activities to identify at-risk patients.

Agenda

 

Friday, March 8

Time (ET)

Presentation

Faculty

5:00pm

Introduction, Program Goals and Logistics

Saurabh Malhotra, MD, MPH, FASNC
5:05pm ASNC's role in amyloidosis education Lawrence Phillips, MD, FASNC

Session 1: Disease and Pathogenesis | Moderator: Saurabh Malhotra, MD, MPH, FASNC

5:10pm 

Structure of amyloid fibrils and mechanism of organ deposition

  • Case presentation

Yvonne Eisele, PhD

5:40pm

Manifestation and early recognition of amyloidosis

  • Case presentation

David Wolinsky, MD, MASNC

6:10pm

Evaluation of polyneuropathy in amyloidosis

  • Case presentation

Sasha Zivkovic, MD, PhD

6:40pm

Prognostic markers in amyloidosis

  • Case presentation

Andrew Staron, MD

7:10pm

Summary and closing comments

Saurabh Malhotra, MD, MPH, FASNC

Saturday, March 9

10:00am

Introduction to Day 2

Saurabh Malhotra, MD, MPH, FASNC

Session 2: Diagnostic Techniques and Pitfalls: A Case-Based Discussion | Moderator: David Wolinsky, MD, MASNC

10:05am

Routine and advanced echocardiography techniques

  •  Case presentation

Matthew Parker, MD

10:35am

Cardiac magnetic resonance for diagnosis and disease management

  •  Case presentation

Sarah Cuddy, MD

11:05am

Nuclear scintigraphy with bone avid tracers: Basics and beyond

  • Case presentation

Saurabh Malhotra, MD, MPH, FASNC

11:35am

Amyloid mutations and role of genetic testing

  • Case presentation

Ashutosh Wechalekar, MBBS, MD

12:05pm

Final comments

Faculty

Break

Session 3: Management | Moderator: Saurabh Malhotra, MD, MPH, FASNC

1:00pm

Differentiating TTR from myeloma precursors

  • Case presentation

Ashutosh Wechalekar, MBBS, MD

1:30pm

Therapeutic landscape in ATTR: Approved and on the horizon

  • Case presentation

Prem Soman, MD, PhD, MASNC

2:00pm

Evaluation and management of cardiac rhythm disorders

  • Case presentation

Mazen Hanna, MD

2:30pm

Management of HF and supportive therapies

  • Case presentations

Ahmad Masri, MD

3:00pm

Closing comments

Faculty

3:15pm

Adjourn

Sunday, March 10

10:00am

Introduction to Day 3

Saurabh Malhotra, MD, MPH, FASNC

Session 4: Facilitating Diagnosis and Management of ATTR | Moderator: Saurabh Malhotra, MD, MPH, FASNC

10:05am

Role of tissue diagnosis and challenges

  • Case presentation

Angela Dispenzieri, MD

10:35am

Community outreach and education

  • Case presentation

Isabelle Lousada

11:05am

Requisites for an amyloidosis center

  • Case presentation

Prem Soman, MD, PhD, MASNC

11:35am

Role of interdisciplinary care teams

  • Case presentation

Melissa Lyle, MD

12:05pm
 

Q&A

Session 5: Challenging Case Studies in Amyloidosis | Moderator: Wael Jaber, MD

1:00pm

Red flag vs red herring

Vasvi Singh, MD, FASNC

1:15pm

Al or ATTR, that is the question

Andrew Staron, MD

1:30pm

PYP doesn’t fit. Must you acquit?

Saurabh Malhotra, MD, MPH, FASNC

1:45pm

Novel amyloid tracers to the rescue

Sharmila Dorbala, MD, MPH, MASNC

2:00pm

Gene positive, PYP negative, heart failure: To treat or not to treat

Ahmad Masri, MD

2:15pm

Finding amyloidosis in a stack of polyneuropathies

Sasha Zivkovic, MD

2:30pm

No amyloid under the microscope: Imaging and pathology discordance

Angela Dispenzieri, MD

2:45pm

Q&A and closing comments

Saurabh Malhotra, MD, MPH, FASNC

*Credits subject to change.



NEW Session for Technologists

Saturday, March 9 
Amyloidosis for Technologists: Tips and Tricks from Experts
1:00pm Welcome and logistics David Wolinsky, MD, MASNC
1:05pm Overview of cardiac Amyloidosis David Wolinsky, MD, MASNC
1:30pm Radionuclide image acquisition and processing for ATTR cardiac amyloidosis on Nal systems Monica Malecki, CNMT
2:00pm Radionuclide image acquisition and processing for ATTR cardiac amyloidosis on CZT systems Joseph Dietz, CNMT
2:30pm Artifacts and pitfalls, and how to avoid them? Mark Hyun, CNMT, NCT, FASNC
3:00pm Final questions Faculty


Learning Objectives for Technologists:

By the end of the program, you should be able to:

  • Describe the importance of differentiating amyloid transthyretin cardiac amyloidosis from light-chain amyloidosis.
  • Compare technetium-99m labelled HMDP and PYP for diagnosis of cardiac amyloidosis.
  • Summarize key parameters acquisition and processing of technetium-99m labelled bone avid tracers with NaI and CZT camera systems.
  • Identify artifacts and common pitfalls associated with technetium-99m labelled bone avid tracers for detecting cardiac amyloidosis.



back to the top

This program is supported by an unrestricted educational grant from Pfizer, Inc.


Logged-In Members: Renew
New Users: Create an Account